Zymeworks Q2 net loss $45M; PDUFA for zanidatamab Aug 25; Theravance acquisition on track

Zymeworks Inc.

Net loss of $45.0M in Q2 2026 vs net income of $2.3M in Q2 2025; revenue fell to $4.6M from $48.7M.
Cash and marketable securities $322.5M as of June 30, 2026; repurchased $49.4M of shares under new $125M program.
PDUFA target date Aug 25, 2026 for zanidatamab in 1L HER2+ GEA; potential $250M U.S. approval milestone.
Acquisition of Theravance Biopharma expected to close 2H 2026, adding YUPELRI profit share and ~$60M annualized cash flow.
R&D expenses down 20% YoY to $27.4M; G&A up to $19.3M on higher stock comp.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.